Galectin-3 Level in Ankylosing Spondylitis Patients

April 17, 2021 updated by: Gul Devrimsel, Recep Tayyip Erdogan University Training and Research Hospital

Relationship Between Galectin-3 Level and Disease Activity in Ankylosing Spondylitis Patients

Forty-five AS patients and 35 healthy controls were enrolled in this study. Patients diagnosed with AS according to Modified New York criteria were included in the study. Clinical and laboratory measurements, duration of symptoms, age and body mass index (BMI) of AS patients were performed and compared with age and BMI matched control group.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Detailed histories of all participants were obtained, and systemic and rheumatologic examinations were performed. We excluded all participants who had a history of hyperlipidemia, liver, renal, hematological, familial thyroid, neoplastic, autoimmune infectious diseases and receiving anti-inflammatory drugs.

We measured serum galectin-3 levels using a commercial chemiluminescent microparticle immunoassay. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess disease activity in AS patients.

Study Type

Observational

Enrollment (Actual)

80

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Ankylosing spondylitis patients and healthy controls

Description

Inclusion Criteria:

  • Ankylosing spondylitis patients
  • Healthy controls

Exclusion Criteria:

  • Hyperlipidemia
  • Liver diseases
  • Renal diseases
  • Hematological diseases
  • Familial thyroid diseases
  • Neoplastic diseases
  • Autoimmune infectious diseases
  • Receiving anti-inflammatory drugs.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
45 ankylosing spondylitis patients.
Patients diagnosed with ankylosing spondylitis according to Modified New York criteria were included in the study.
Other: Serum galectin-3 concentration was measured.
Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.
35 controls
Healthy controls
Other: Serum galectin-3 concentration was measured.
Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Relationship Between Galectin-3 Level and Disease Activity in Ankylosing Spondylitis Patients
Time Frame: 5 months
Correlation
5 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Recep Tayyip Erdogan University Training and Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2017

Primary Completion (ACTUAL)

June 30, 2017

Study Completion (ACTUAL)

August 30, 2017

Study Registration Dates

First Submitted

February 4, 2021

First Submitted That Met QC Criteria

February 8, 2021

First Posted (ACTUAL)

February 9, 2021

Study Record Updates

Last Update Posted (ACTUAL)

April 20, 2021

Last Update Submitted That Met QC Criteria

April 17, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2016/85

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ankylosing Spondylitis

Clinical Trials on Serum galectin-3 concentration was measured.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe